0001415889-22-012301.txt : 20221209 0001415889-22-012301.hdr.sgml : 20221209 20221209160721 ACCESSION NUMBER: 0001415889-22-012301 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221207 FILED AS OF DATE: 20221209 DATE AS OF CHANGE: 20221209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KELER TIBOR CENTRAL INDEX KEY: 0001429931 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 221454837 MAIL ADDRESS: STREET 1: 30 PARK ROAD CITY: OTTSVILLE STATE: PA ZIP: 18942 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-12092022_091203.xml X0306 4 2022-12-07 0000744218 Celldex Therapeutics, Inc. CLDX 0001429931 KELER TIBOR C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false EXECUTIVE VP & CSO Common Stock, par value $0.001 per share 2022-12-07 4 M 0 16860 2.78 A 24217 D Common Stock, par value $0.001 per share 2022-12-07 4 S 0 16860 36.9283 D 7357 D Incentive Stock Option (right to buy) 2.78 2022-12-07 4 M 0 16860 0 D 2029-06-19 Common Stock 16860 43140 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.28 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Samuel B. Martin, attorney-in-fact for Tibor Keler 2022-12-09